Background & Aims Physicians frequently encounter patients with immune-mediated
diseases and a history of malignancy. There are limited data on the safety of …

Psoriasis is a chronic immune-mediated disease associated with several co-morbidities and
negative impacts on a patient's quality of life. Despite the advances in biologic therapy, there …

Background Real‐life data on newer biological and biosimilar agents for moderate‐to‐
severe psoriasis are lacking. Objectives To examine safety, efficacy and time to …

Objective Drug survival is an important proxy measure for effectiveness of treatments for
inflammatory diseases such as rheumatoid arthritis (RA), axial spondyloarthritis (AxSpA) …

Background The effect of systemic therapy on malignancy risk among patients with psoriasis
is not fully understood. Objective Evaluate the impact of systemic treatment on malignancy …

Abstract The German Psoriasis Registry PsoBest was conducted in 2008 in order to
investigate the long-term outcomes and safety of systemic treatments for moderate-to-severe …

Background Anti–tumor necrosis factor (TNF) therapy in psoriasis has been associated with
an increased risk of serious infections compared with nonbiologic systemic therapies …

Psoriasis is an inflammatory and chronic skin disorder associated with physical and
psychological burden impairing patients' quality of life. In the last decade, biologic drugs …

Background Registry studies broadly describing the safety of systemic drugs in psoriasis are
needed. Objective To describe the safety findings of the systemic drugs acitretin …

Importance There is a need for better understanding of the comparative safety of systemic
medications used in the treatment of psoriasis. Objective To compare the risk of serious …